Practical implication
Update labeling to reflect the new indication for Stelara, and ensure compliance with associated regulatory activities including safety monitoring.
Stelara (ustekinumab) has received FDA approval for treating pediatric patients aged 2 years and older with moderately to severely active ulcerative colitis (UC). This is the first monoclonal antibody approved for pediatric inflammatory bowel disease that does not target TNFα.
What changed: Stelara is now approved for a new indication—treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients aged 2 years and older.
Why it matters: This approval expands the therapeutic options available for pediatric patients suffering from UC, a chronic condition that can lead to significant health complications.
Practical implication: Update labeling to reflect the new indication for Stelara, and ensure compliance with associated regulatory activities including safety monitoring.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-08-28T00:00:00.000Z
- Discovered by monitor: 2026-08-29T05:18:34.613Z
Published from the regulator source ingestion pipeline after PV impact triage.
